Development of papulopustular rosacea during nivolumab therapy for metastatic cancer

Acta Dermato-Venereologica

Volumn 97, Issue 4, 2017, Pages 539-540

  Bousquet, Emilie ^a   Zarbo, Allison ^b   Tournier, Emilie ^c   Chevreau, Christine ^d   Mazieres, Julien ^a   Lacouture, Mario E ^e   Sibaud, Vincent ^d  

^a SERVICE DE PNEUMOLOGIE   (France)

^b HENRY FORD HOSPITAL   (United States)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

^d INSTITUT CLAUDIUS REGAUD   (France)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; DOXYCYCLINE; METRONIDAZOLE; NIVOLUMAB; PROGRAMMED DEATH 1 LIGAND 1; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; CELL INFILTRATION; CLINICAL ARTICLE; DISEASE EXACERBATION; ERYTHEMA; FACE RASH; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LUNG CANCER; MACULOPAPULAR RASH; MALE; MELANOMA; METASTASIS; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NOTE; PAPULE; PAPULOSIS; PRIORITY JOURNAL; PUSTULE; ROSACEA; SKIN BIOPSY; T LYMPHOCYTE; TONSIL CARCINOMA; VERY ELDERLY; BIOPSY; CHEMICALLY INDUCED; CUTANEOUS DRUG ADMINISTRATION; DRUG EFFECTS; DRUG ERUPTIONS; FACIAL DERMATOSES; NEOPLASMS; PATHOLOGY; SKIN; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ANTI-INFECTIVE AGENTS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOPSY; DRUG ERUPTIONS; FACIAL DERMATOSES; FEMALE; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASMS; ROSACEA; SKIN; TREATMENT OUTCOME;

EID: 85017213515     PISSN: 00015555     EISSN: 16512057     Source Type: Journal    
DOI: 10.2340/00015555-2566     Document Type: Note

References (8)

1. Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti PD-1 therapy. Eur J Cancer 2016; 60: 190–209.
2. Sibaud V, Meyer N, Lamant L, Vigarios E, Mazieres J, Delord JP. Dermatologic complications of anti PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol 2016; 28: 254–263.
3. Belum VR, Benhuri B, Postow MA, Hellmann MD, Lesokhin AM, Segal NH, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer 2016; 60: 12–25.
4. Matsumura N, Ohtsuka M, Kikuchi N, Yamamoto T. Exacerbation of psoriasis during nivolumab therapy for metastatic melanoma. Acta Derm Venereol 2016; 96: 259–260.
5. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372: 2018–2028.
6. Melnik B. Rosacea: the blessing of the celts -An approach to pathogenesis through translational research. Acta Dermatol Venereol 2016; 96: 147–156.
7. Buhl T, Sulk M, Nowak P, Buddenkotte J, McDonald I, Aubert J, et al. Molecular and morphological characterization of inflammatory infiltrate in rosacea reveals activation of Th1/Th17 pathways. J Invest Dermatol 2015; 135: 2198–2208.
8. Dulos J, Carven GJ, van Boxtel SJ, Buddenkotte J, McDonald I, Aubert J, et al. PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother 2012; 35: 169–178.